Connect With Us
Subscribe Now
Log In
Home
News
Education
Health
Tech
STEM
Advanced Manufacturing & Logistics
Life Sciences
Ag INnovation
INPower
Videos
Big Wigs
Submit Big Wigs
Events
Innovate Southwest Indiana â Evansville
Innovate West Central Indiana – Terre Haute
Innovate East Central – Muncie
Innovate Northeast Indiana – Fort Wayne
Newsletters
Podcasts
On-Air
TV & Radio Listings
Content Studio
Sponsored Content
Contact
About IIB
Meet the Team
Contact Us
Advertise
Gift Cards
Flagship Stations
Gerry’s Message
Speaking Engagement Request
Search
GO
Connect With Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
463.86
-5.82 (-1.24%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vertex Pharmaceuticals
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
69
70
Next >
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
↗
December 20, 2024
The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
December 19, 2024
Via
Benzinga
Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?
↗
December 19, 2024
Vertex Pharmaceuticals' suzetrigine reduced pain in Phase 2 trials for lumbosacral radiculopathy. Plans for Phase 3 trials follow regulatory discussions.
Via
Benzinga
Vertex Plunges 10% After Its Non-Opioid Pain Drug Flops In Lower Back Pain
↗
December 19, 2024
The company says there was variability among placebo responses at various sites.
Via
Investor's Business Daily
Vertex Non-Opioid Drug Doesn't Best Placebo In Back Pain Study. The Stock Is Plunging.
↗
December 19, 2024
Vertex Pharmaceuticals' drug reduced back pain significantly.
Via
Investor's Business Daily
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
↗
December 13, 2024
Via
Benzinga
The Ultimate Biotech Stock to Buy With $500 Right Now
↗
December 12, 2024
Via
The Motley Fool
Looking Into Vertex Pharmaceuticals's Recent Short Interest
↗
November 25, 2024
Via
Benzinga
Got $500? 1 Biotech Stock to Buy and Hold Forever
↗
November 22, 2024
Via
The Motley Fool
Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
December 19, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
2 Unstoppable Stocks to Buy and Hold for the Next Decade
↗
December 19, 2024
Via
The Motley Fool
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?
↗
December 17, 2024
Via
The Motley Fool
Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday
↗
December 16, 2024
Via
Benzinga
A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics
↗
November 18, 2024
Via
Benzinga
Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030
↗
December 16, 2024
Via
The Motley Fool
3 Unstoppable Stocks to Buy Right Now
↗
December 15, 2024
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
↗
December 10, 2024
Via
Benzinga
Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock
↗
December 09, 2024
Jefferies upgrades Vertex Pharmaceuticals to Buy, highlighting a promising pipeline and $5 billion-$7 billion growth potential from pain and kidney treatments.
Via
Benzinga
A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 19 Analysts
↗
December 09, 2024
Via
Benzinga
2 No-Brainer Stocks to Buy Before the End of 2024
↗
December 09, 2024
Via
The Motley Fool
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update
December 08, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
3 No-Brainer Growth Stocks to Buy in December
↗
December 07, 2024
Via
The Motley Fool
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?
↗
December 05, 2024
Via
The Motley Fool
FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program
↗
December 04, 2024
CMS launches an outcomes-based model to expand access to FDA-approved gene therapies for sickle cell disease, aiming to improve health outcomes and lower costs.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
December 04, 2024
Via
Benzinga
It’s Been A Tough Month For Healthcare Stocks
↗
December 02, 2024
It’s been a very difficult month for the healthcare sector not only because of disappointing company news but also disruption caused by the election and future policy issues.
Via
Talk Markets
Topics
ETFs
Stocks / Equities
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.
↗
November 28, 2024
Via
The Motley Fool
Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?
↗
November 24, 2024
Via
The Motley Fool
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
↗
November 18, 2024
Via
The Motley Fool
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
↗
November 16, 2024
Via
The Motley Fool
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
69
70
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
